Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
Zacks·18h ago
More News
CVS or HQY: Which Is the Better Value Stock Right Now?
CVS vs. HQY: Which Stock Is the Better Value Option?
Zacks·7d ago
HQY Expands Access With GLP-1 Telehealth & Direct HSA Platforms
HealthEquity rolls out GLP-1 telehealth and direct HSA enrollment platforms, targeting affordability and growth amid rising healthcare costs and regulatory expansion.
Zacks·8d ago
Here's Why HealthEquity (HQY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·11d ago
Reasons to Add HealthEquity Stock to Your Portfolio for Now
HQY's strong Q2, expanding HSAs and AI-driven efficiencies highlight its growth momentum despite data security risks.
Zacks·12d ago
HealthEquity (HQY) Down 5.1% Since Last Earnings Report: Can It Rebound?
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·26d ago
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·1mo ago
Why HealthEquity (HQY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·1mo ago
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·2mo ago
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.